We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.51B
AUM Growth
+$203K
Cap. Flow
-$184M
Cap. Flow %
-4.08%
Top 10 Hldgs %
82.68%
Holding
115
New
24
Increased
20
Reduced
23
Closed
20

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$15.8M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$11.2M
3
MET icon
MetLife
MET
+$10.7M
4
TSRO
TESARO, Inc.
TSRO
+$8.14M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$7.5M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$41.4M
2
BLUE
bluebird bio
BLUE
+$13.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.9M
4
CELG
Celgene Corp
CELG
+$12M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.24M

Sector Composition

Rank Sector Weight
1 Consumer Staples 44.81%
2 Healthcare 28.52%
3 Consumer Discretionary 10.77%
4 Financials 0.73%
5 Industrials 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
51
DELISTED
Array Biopharma Inc
ARRY
$6.71M 0.15%
750,000
-500,000
-40% -$5.32M
JNCE
52
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$6.6M 0.15%
+300,000
New +$6.36M
GBT
53
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.45M 0.14%
175,000
-71,054
-29% -$1.79M
ARAV
54
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.41M 0.14%
+50,000
New +$5.27M
ALDR
55
DELISTED
Alder Biopharmaceuticals
ALDR
$6.24M 0.14%
+300,000
New +$6.64M
SRPT icon
56
Sarepta Therapeutics
SRPT
$1.64B
$5.92M 0.13%
200,000
– –
AGIO icon
57
CALL
Agios Pharmaceuticals
AGIO
$2.08B
$5.84M 0.13%
100,000
-500,000
-83% -$24M
MGNX icon
58
MacroGenics
MGNX
$233M
$5.58M 0.12%
300,000
+100,000
+50% +$1.93M
ACIU icon
59
AC Immune
ACIU
$231M
$5.18M 0.12%
500,000
+250,000
+100% +$3.07M
MDCO
60
DELISTED
Medicines Co
MDCO
$4.89M 0.11%
100,000
+50,000
+100% +$2.28M
SGEN
61
DELISTED
Seagen Inc. Common Stock
SGEN
$4.71M 0.1%
+75,000
New +$4.68M
LRMR icon
62
Larimar Therapeutics
LRMR
$377M
$4.66M 0.1%
83,333
+41,666
+100% +$2.07M
JUNO
63
DELISTED
Juno Therapeutics, Inc.
JUNO
$4.44M 0.1%
200,000
– –
LCTX icon
64
Lineage Cell Therapeutics
LCTX
$264M
$4.42M 0.1%
1,465,383
– –
BMRN icon
65
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
$4.39M 0.1%
50,000
-100,000
-67% -$8.9M
BCRX icon
66
BioCryst Pharmaceuticals
BCRX
$2.42B
$4.2M 0.09%
+500,000
New +$3.48M
CCXI
67
DELISTED
ChemoCentryx, Inc.
CCXI
$3.98M 0.09%
546,278
– –
AIMT
68
DELISTED
Aimmune Therapeutics
AIMT
$3.95M 0.09%
181,600
+100,000
+123% +$2.05M
SIOX
69
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.73M 0.08%
31,250
-6,250
-17% -$655K
INTC icon
70
Intel
INTC
$413B
$3.61M 0.08%
+100,000
New +$3.62M
CLLS
71
Cellectis
CLLS
$288M
$3.6M 0.08%
150,000
– –
NTLA icon
72
Intellia Therapeutics
NTLA
$1.51B
$3.52M 0.08%
250,000
– –
IMUX icon
73
Immunic
IMUX
$178M
$3.5M 0.08%
+2,188
New +$4.01M
CMRX
74
DELISTED
Chimerix, Inc.
CMRX
$3.19M 0.07%
500,000
– –
RGNX icon
75
Regenxbio
RGNX
$616M
$3.09M 0.07%
160,000
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2017 Portfolio in Review

As of Q1 2017, Artal Group held 115 positions worth $4.51B, up 0% from $4.5B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group withdrew a net $184M in Q1 2017, closing 20 positions and reducing 23 holdings. Its most notable exit was Celgene Corp, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 45% of assets, down from 47% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Ionis Pharmaceuticals worth $10.1M.

  • Artal Group's largest Q1 2017 buy was Ionis Pharmaceuticals: 250,000 shares worth $10.1M.
  • Artal Group added most to Acceleron Pharma in Q1 2017, an estimated $15.8M increase.
  • Artal Group's biggest Q1 2017 reduction was Incyte, cutting an estimated $41.4M.
  • Artal Group fully exited Celgene Corp in Q1 2017, selling an estimated $12M.
  • Artal Group's ten largest holdings make up 83% of its $4.51B portfolio in Q1 2017.
  • Artal Group opened 24 new positions and closed 20 in Q1 2017.
  • Artal Group's portfolio value rose 0% quarter-over-quarter to $4.51B.

Based on Artal Group's 13F filing for Q1 2017, filed 15 May 2017.